EG 427, a French biotech company, has raised €27M in a Series B funding round led by Andera Partners and Bpifrance, with participation from the InnoBio investment strategy.

EG 427 develops pinpoint genetic medicines for prevalent chronic diseases in neurology, specialising in non-replicating HSV-1 (nrHSV-1) vector technology in neurology. The company plans to to use the funds to finance phase 1b/2a study of its lead product, EG110A, through safety and early efficacy results as well as supporting its early-stage pipeline which is based on its proprietary HERMES vector technology platform. EG110A was developed for the treatment of severe bladder diseases, such as neurogenic bladder (NDO) and overactive bladder (OAB).